

UCSF

UC San Francisco Previously Published Works

Title

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Permalink

<https://escholarship.org/uc/item/5405b8hc>

Journal

Nature, 468(7323)

ISSN

0028-0836

Authors

Junttila, Melissa R
Karnezis, Anthony N
Garcia, Daniel
et al.

Publication Date

2010-11-01

DOI

10.1038/nature09526

Peer reviewed



Published in final edited form as:

Nature. 2010 November 25; 468(7323): 567–571. doi:10.1038/nature09526.

Selective activation of p53-mediated tumour suppression in high-grade tumours

Melissa R. Junttila¹, Anthony Karnezis¹, Daniel Garcia¹, Francesc Madriles², Roderik M. Kortlever¹, Fanya Rostker¹, Lamorna Brown-Swigart¹, David M. Pham³, Youngho Seo³, Gerard I. Evan^{1,4,5}, and Carla P. Martins^{1,2}

¹University of California San Francisco, Department of Pathology and Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0502, USA.

³University of California San Francisco, Department of Radiology and Biomedical Imaging and Helen Diller Family Comprehensive Cancer Center San Francisco, California 94143, USA.

Summary

Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide, with an overall 5-year survival rate of only 10–15% ¹. Deregulation of the Ras pathway is a frequent hallmark of NSCLC, often through mutations that directly activate Kras ². p53 is also frequently inactivated in NSCLC and, since oncogenic Ras can be a potent trigger of p53 ³, it seems likely that oncogenic Ras signalling plays a major and persistent part in driving the selection against p53. Hence, pharmacological restoration of p53 is an appealing therapeutic strategy for treating this disease ⁴. Here, we model the likely therapeutic impact of p53 restoration in a spontaneously evolving mouse model of NSCLC initiated by sporadic oncogenic activation of endogenous Kras ⁵. Surprisingly, p53 restoration failed to induce significant regression of established tumours although it did result in a significant decrease in the relative proportion of tumours classed as high grade. This is due to selective activation of p53 only in the more aggressive tumour cells within each tumour. Such selective activation of p53 correlates with marked up regulation in Ras signal intensity and induction of the oncogenic signalling sensor p19^{ARF} ⁶. Our data indicate that p53-mediated tumour suppression is triggered only when oncogenic Ras signal flux exceeds a critical threshold. Importantly, the failure of low-level oncogenic Kras to engage p53 reveals inherent limits in the capacity of p53 to restrain early tumour evolution and to the efficacy of therapeutic p53 restoration to eradicate cancers.

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

⁵Corresponding author: gie20@cam.ac.uk.

²Present address: Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.

⁴Present address: Department of Biochemistry, Tennis Court Road, University of Cambridge, Cambridge CB2 1GA, UK.

AUTHOR CONTRIBUTIONS

C.P.M. designed this study with help from M.R.J. and G.I.E. C.P.M. and M.R.J. performed all experiments with assistance from D.G. and F.M.. C.P.M., M.R.J. and G.I.E. analyzed and interpreted the data. A.K. graded all tumours. D.M.P. and Y.S. performed the MicroCT analysis. F.R. and R.K. helped maintain the mouse colony. C.P.M. and G.I.E. wrote the paper with help from M.R.J. and all authors contributed to editing.

Inactivation of the p53 tumour suppressor pathway is a common feature of human cancers, fostering the attractive notion of restoring p53 function in established tumours as an effective and tumour-specific therapeutic strategy 4. Indeed, p53 restoration was recently shown to trigger dramatic tumour regression *in vivo* 7–9. While encouraging, these studies utilized tumour models (either transgene 7,9 or radiation-induced 8) driven by preternaturally high levels of oncogenes. Because high-level oncogene activity potently engages p53 via the p19^{ARF} tumour suppressor 6,7,10, p53 restoration has a dramatic impact in these models. Unlike high oncogenic activity, however, low-level expression of dominant oncogenes appears insufficient to engage intrinsic tumour suppression, even though it still suffices to drive tumourigenesis 11,12. This raises the spectre that many epithelial malignancies, initiated as they are by low-level oncogenic signals such as those arising from mutational activation of *ras* genes *in situ*, may be insensitive to p53 restoration - at least during certain phases of their evolution. To investigate this possibility we assessed the ability of p53 restoration to trigger tumour regression in the well-characterized *Lox-Stop-Lox-Kras^{G12D}* (*KR*) murine tumour model of NSCLC 5 wherein tumourigenesis is driven by sporadic, low-level activation of mutant Kras. This model closely recapitulates its human disease counterpart 13.

After inhalation of adenovirus-Cre, *KR* mice develop multiple, independently evolving lung tumours, permitting contemporaneous analysis of different disease stages within each animal. *KR* mice were crossed into the *p53^{KI/KI}* switchable mouse model in which both alleles of the endogenous *p53* gene are replaced by the conditional variant *p53^{ERTAM}* 14. *p53^{KI/KI}* mice can be reversibly toggled *in vivo* between p53 wild-type (*wt*) and p53 null states by administration or withdrawal of Tamoxifen (Tam). Importantly, once functionally restored in Tam-treated *p53^{KI/KI}* mice, p53-mediated tumour suppression is triggered only if p53-activating signals are present 7,10.

Kras^{G12D} was sporadically activated in *KR;p53^{KI/+}* and *KR;p53^{KI/KI}* lungs and tumours allowed to develop for 16 weeks. In both genotypes, *Kras^{G12D}* activation induced a spectrum of lung tumour grades including hyperplasias, adenomas and adenocarcinomas. Like *KR;p53*-deficient animals 15 (Supplementary Figure 1), *KR;p53^{KI/KI}* mice exhibit accelerated tumour progression and increased incidence of high-grade tumours relative to their *KR;p53^{KI/+}* counterparts. These data affirm that p53 restrains Kras-driven NSCLC yet indicate that, even when combined, *Kras^{G12D}* activation and *p53* inactivation are insufficient to generate malignant tumours without additional, aleatory mutations.

To ascertain its therapeutic impact, p53 function was restored for one week in *KR;p53^{KI/KI}* lung tumours (Figure 1A). Surprisingly, given the dramatic tumour regression induced by p53 restoration in other models 7–9, p53 restoration had no macroscopically evident impact on these tumours (Figure 1B). Close inspection, however, indicated that p53 restoration did elicit a modest decrease in proliferating tumour cells (Figure 1C; 13.99% Ki67 positive cells per Tam-treated tumours versus 20.97% in controls) and an increase in apoptosis (Supplemental Figure 2 and Figure 1D; 45% of p53-restored tumours contain apoptotic cells versus 13.5% of control tumours). Nevertheless, the distribution of apoptotic cells in tumours following p53 restoration was irregular and clustered (Figure 1E). This high variability in the response to sustained p53 restoration was confirmed by microCT imaging

of individual tumours over 7 days. While all control tumours grew during treatment, individual Tam-treated tumours exhibited all possible responses – some grew, others were unchanged, and many shrank (Figure 2A and Supplemental Figure 3). Such variability in tumour response to Tam might reflect heterogeneities among tumor cells in the efficiency of p53 restoration, in the presence of p53-activating signals, or in the engagement of downstream effectors following p53 restoration. To determine which, we first ascertained the efficiency with which Tam restored p53 function in tumours. Mice were treated for 7 days with Tam or vehicle and then exposed to a single dose of γ -radiation (IR) 2 hrs after the last treatment to activate p53 directly. p53 activity was then monitored in individual tumours by assaying induction of the prototypical p53-responsive gene, *CDKN1A* (*p21^{cip1}*) 16,17. All tumours showed substantial *CDKN1A* induction (Figure 2B), indicating that systemic Tam pervasively restores p53 function in all tumours. Hence, the heterogeneity of the therapeutic response to Tam is not a consequence of either variability in Tam-dependent p53 restoration or in the capacity of p53, once activated, to induce *CDKN1A*. By contrast, when p53 function was restored in the absence of concomitant DNA damage, *CDKN1A* was induced in only a minority of tumours (Figure 2B). Hence, the variability in response to p53 restoration is because only a minority of tumours harbour endogenous p53-activating signals. Interestingly, whereas we see abundant apoptosis in aggressive tumour cells following p53 restoration, Feldser *et al.* in an accompanying paper do not 18, even though their mouse lung tumour model driven by spontaneous, sporadic KRas activation is ostensibly similar to ours. The reasons for this are unclear. However, the models differ in several ways. First, the mechanism of KRas activation is different, and may target distinct cell lineages with innately different sensitivities to p53-induced apoptosis. Second, they use Cre-lox recombination to restore p53 function, which is innately less synchronous than in our p53ER^{TAM} model and may make it difficult to see a transient wave of cell death. Cre-lox recombination may also introduce additional genotoxic stresses that further modify p53 output. In the end, however, whether apoptosis or senescence is the principal output of p53 restoration in aggressive tumour cells may not be so important since that both p53-induced apoptosis 7 and senescence 9 are effective at eliciting tumour clearance.

Although p53 may be activated by a wide-range of stress signals, recent *in vivo* studies implicate induction of p19^{ARF} by oncogenic signalling as the critical p53-activating trigger in established tumours 7,10. Since oncogenic Ras can be a potent inducer of p19^{ARF} 19, we assayed for p19^{ARF} expression in *KR;p53^{KI/KI}* lung tumours. Immunohistochemical analysis (IHC) of *KR;p53^{KI/KI}* lungs revealed p19^{ARF} expression to be highly heterogeneous – generally limited to specific regions of certain tumours. Stratification of lung tumours into low and high-grade, the latter comprising mostly adenocarcinomas (Supplemental Figure 4) 20, revealed that p19^{ARF} was confined mostly to high-grade tumours. High p19^{ARF} cells were only rarely observed in low-grade tumours and, when present, were restricted to small, sporadic foci. Close examination of transitional tumours comprising clearly defined high and low-grade regions showed p19^{ARF} to be highly expressed only in high-grade/carcinoma areas (Figure 2C).

Since p19^{ARF} is a potent activator of p53, we next ascertained whether the high-grade regions expressing elevated p19^{ARF} coincide with those that spontaneously activate p53

following restoration. p53 function was acutely restored in *KR;p53^{KI/KI}* mice and tumours analyzed for expression of p19^{ARF} and p21^{cip1}. Upon p53 restoration, tumour areas positive for p19^{ARF} overlapped extensively with those positive for p21^{cip1} (Figure 2D): ~70% of p19^{ARF}-positive cells from Tam-treated mice stained positive for p21^{cip1} compared with 2% of control. That p19^{ARF} plays a causal role in engaging p53-mediated tumour suppression in high-grade tumours was corroborated by the rapid cessation of cell proliferation specific to p19^{ARF}-positive regions following p53 restoration (Figure 3A – Tam, two upper rows). By contrast, proliferation remained high in p19^{ARF}-negative tumours after p53-restoration (Figure 3A – Tam, two lower rows). Of note, no γ -H2AX staining DNA damage foci were detected in *KR;p53^{KI/KI}* lung tumours, although they were readily evident in tumours from γ -irradiated mice (Supplemental Figure 5). The remarkable overlap between p53 activation and p19^{ARF} expression strongly implicates p19^{ARF}, and not DNA damage, as the endogenous signal responsible for triggering p53 in high-grade lung tumours.

Although germ-line *p53* deficiency significantly accelerates lung tumour progression and malignancy in *KR* mice 15, our data indicate that p53 tumour suppression acts only at later stages of tumour evolution. Since p53 is specifically activated in the most aggressive tumour cells, its restoration in a mixed tumour population should lead to a shift downwards in assigned tumour grade. Indeed, 7 days of p53 restoration in *KR;p53^{KI/KI}* mice harbouring a mixture of low and high-grade tumours elicited a downward shift in the frequency of high-grade tumours (from 29% to 11%) and a *pro rata* increase in the proportion of low-grade tumours (from 71% to 89%) (Figure 3B and Supplemental Figure 6). The percentage of BrdU-positive high-grade cells was also dramatically reduced following treatment (Figure 3C).

Our data show that the p19^{ARF}/p53 pathway is only engaged in high-grade *KR;p53^{KI/KI}* cells, even though all tumour cells harbour oncogenic *Kras^{G12D}*. Hence, oncogenic activity of *Kras* is not alone sufficient to induce p19^{ARF} and engage p53-mediated tumour suppression. Interestingly, recent *in vivo* studies indicate that intrinsic tumour suppression is only engaged when oncogenic signals are preternaturally elevated 11,12. Such observations echo *in vitro* data showing that expression of oncogenic *Kras^{G12D}* from its endogenous promoter induces proliferation and immortalization whereas *Kras^{G12D}* over-expression engages p53-dependent replicative senescence 21,22. Since marked up-regulation of the MAPK-pathway is a characteristic feature of advanced lung tumours in both mice 15 and NSCLC in humans 23, we asked whether induction of p19^{ARF} in high-grade tumours is a consequence of elevated flux through the Ras signalling network. Indeed, immunostaining showed a remarkably tight spatial concordance of tumour cells exhibiting elevated ERK phosphorylation (p-ERK), a signature of downstream Ras signalling, and those with high p19^{ARF} (Figures 4A and Supplemental Figure 7) – the cell-by-cell overlap between up-regulation of p19^{ARF} and p-ERK was 91.2% (n=1312; STDEV: 3.77). Hence, increased flux through oncogenic *Kras^{G12D}* is the likely mechanism for both malignant progression and concomitant activation of (and eventual counter-selection against) the p19^{ARF}/p53 tumour suppressor pathway.

Many potential mechanisms might underlie the dramatic up-regulation of p-ERK we observe in high-grade lung tumours, including changes in *Kras* copy number (known to occur in

human NSCLC), secondary inactivation of the wt *Kras* allele, inactivation of *Kras* negative feedback mechanisms and incidental activation of cooperating oncogenes 24–27. Initial analysis of whole low versus high-grade tumours suggested downregulation of Sprouty 2 or loss of the wt *Kras* allele as possible mechanisms for *Kras* signal up-regulation in high p-ERK tumours (Supplemental Figure 8). Since elevated Ras signalling is a property peculiar to high-grade tumour regions, we used p-ERK staining to demarcate high, low and mixed p-ERK areas of individual tumours (Figure 4B, upper panel). These tumour regions were individually laser microdissected and their genomic DNA extracted and assessed for the relative copy representation of wt versus mutant *Kras* alleles. We saw variable levels of wt *Kras* retention in the low/mixed p-ERK tumour tissues, ranging from 100% in the low p-ERK tumour 14 through to partial or total loss in the mixed grade tumours (e.g. 21 and 18). Remarkably, the wt *Kras* allele was lost in all high p-ERK tumours (Figure 4B, lower panel) and the mutant *Kras* allele often duplicated (Supplemental Figure 9). Overall, across all tumour samples *Kras* allelic imbalance, a known mechanism by which Ras signal strength is elevated 27, correlated tightly with high p-ERK.

Long-lived organisms must solve the problem of suppressing cancer without compromising the facility of normal cells to proliferate. This requires an accurate means of distinguishing between normal and oncogenic signals. However, emerging evidence hints at a “flaw” in how our tumour suppressor pathways have evolved – rather than responding to the aberrant signal persistence that is actually responsible for oncogenesis, mammalian intrinsic tumour suppressor pathways have instead evolved to respond to the unusual elevation in signal intensity that often (but not invariably) accompanies oncogenic activation 11. Paradoxically, therefore, low-level oncogenic activities may be more efficient at initiating tumourigenesis than high-level oncogenic signals because they “fall beneath the radar” of tumour surveillance 28: high-level oncogenic signals, which appear necessary to drive progression to malignancy, are tolerable only once p53 function has been quelled.

At first glance, our data showing limited therapeutic impact of restoring p53 in established lung tumours appear at odds with previous studies 7–9. However, such studies utilized advanced, relatively homogenous tumours driven by high levels of oncogenic signalling that had already engaged the ARF pathway – hence the dramatic impact of re-instating p53. By contrast, the spontaneously evolving lung tumours that afflict *KR* mice are initiated by sporadic oncogenic activation of endogenous *Kras* at a level insufficient to engage p53. Our data suggest that it is only relatively late in their evolution, at the point when sporadic elevation of Ras signalling precipitates tumours into aggressive, high-grade lesions, that the p53 pathway is triggered. Such considerations offer a compelling rationale for the long-baffling observation that selection for p53 pathway inactivation arises relatively late in the evolution of many solid human tumours.

The inability of low-level oncogenic signalling to engage p53 also casts a cautionary shadow over the potential efficacy of p53 restoration in treating cancer. Established tumours are typically comprised of heterogeneous clades of neoplastic clones that encompass all phases of oncogenic evolution. Although p53 restoration might cull the most malignant cells, less aggressive tumour cells driven by low-level oncogenic signals would presumably survive to

evolve another day. At best, then, p53 restoration as a single therapy would be a means of temporary tumour containment rather than eradication.

METHODS SUMMARY

Tumour induction and treatment

Animals were maintained under UCSF IACUC-approved protocols. *KR* 5 and *p53^{KI}* mice 14 progeny were infected with Adenovirus-CRE (5×10^7 pfu/mouse) by nasal inhalation at 8 weeks of age 5. p53 function was restored by intraperitoneal injection of Tamoxifen (1 mg/mouse/daily) 7,10,14. Where appropriate, mice were irradiated (4 Gy) 2 hr after Ctrl/Tam treatment using a Mark 1–68 ¹³⁷Cesium source (0.637 Gy/min). A minimum of 5 mice per cohort was used for each experiment.

Immunohistochemistry and immunofluorescence

Primary antibodies used were p19^{ARF} (gift from CJ. Sherr and MF Roussel 29); p21 (BD Pharmigen #556430); Ki67 (SP6 Neomarkers); P-ERK (Cell Signaling Technologies #4376) and phospho-histone H2AX (Upstate #05-636). They were detected with HRP-/Alexa-conjugated secondary antibodies. An ApoptagTM kit (Chemicon) was used for TUNEL.

LCM, expression and copy number analysis

For *CDKN1A* Taqman analysis 8, LCM isolation of frozen samples 30 was followed by RNA preparation (Arcturus PicoPure RNA Isolation kit, Arcturus Engineering) and cDNA production (iScript cDNA Synthesis kit, Bio-Rad). For copy number analysis, LCM (Zeiss P.A.L.M) collection of paraffin samples was followed by DNA isolation (QIAamp[®] DNA Micro Kit #56304) and Taqman (probes: β -Actin: Mm00607939_s1; *Kras*: Mm03053281_s1, Applied Biosystems) or PCR (primers: *Kras*Hind3_F GCCATTAGCTGCTACAAAACAGTA and *Kras*Hind3_R CCTCTATCGTAGGGTCGTACTCAT). Following PCR the *Kras^{G12D}* and *Kras^{wt}* alleles were distinguished by the presence of a *Kras^{G12D}*-specific HindIII site in the amplified fragment (WT = 400 bp; *Kras^{G12D}* = 300 +100 bp).

MicroCT X-Ray Tomography

Pre- (day 0) and post-therapy (day 7) MicroCT data was acquired using a FLEXTM X-OTM system (Gamma Medica-Ideas, Northridge, CA). Only clearly discrete tumours were measured.

Immunoblot Analysis

Whole-cell lysates from dissected tumour halves were immunoblotted with anti-Spry 2 (Abcam ab50317), Dusp6 (Santa Cruz sc-28902) or β -actin (Sigma A5441) antibodies.

METHODS

Mice, adenoviral infection and treatments

Animals were maintained in SPF conditions under UCSF IACUC-approved protocols. *KP* 5 and *p53^{KI}* mice 14 were crossed and *KP* and *KP;p53^{KI/KI}* animals were infected by nasal

inhalation with Adenovirus-CRE (5×10^7 pfu/mouse) at 8 weeks of age, as described 5. p53 function was restored by treating mice with Tamoxifen (1 mg/mouse/daily) delivered by intraperitoneal injection, as described 7,10,14. Where appropriate, mice were irradiated (4 Gy) 2 hr after Ctrl/Tam treatment using a Mark 1–68 137 Cesium source (0.637 Gy/min). A minimum of 5 mice per cohort were used for each experiment.

Immunohistochemistry and immunofluorescence

IHC stainings were performed on z-fix fixed, 5 μ m paraffin embedded tissue sections. Sections were incubated overnight at 4°C with the following primary antibodies: p19^{ARF} (gift from CJ. Sherr and MF Roussel 29); p21 (BD Pharmigen #556430, San Jose, CA); Ki67 (SP6, Neomarkers: Fremont, CA); P-ERK (Cell Signaling Technologies #4376, Danvers, MA), phospho-Histone H2AX (Upstate #05-636, Billerica, MA). Antibodies were detected using Vectastain ABCTM detection (Vector Laboratories, Burlingame, CA) or with specific biotinylated secondaries (anti-Rat biotinylated, Vector Laboratories BA-4001 and anti-Rabbit biotinylated, Dako #E0432) followed with stable diaminobenzidine treatment (Invitrogen, Carlsbad, CA). Alternatively, Alexa-conjugated mouse, rat or rabbit IgG antibodies were used (Molecular Probes). TUNEL staining was performed using the ApoptagTM fluorescein labeled kit (Chemicon) according to the manufacturers directions.

Laser capture microdissection, expression and copy number analysis

For RNA analysis 30 μ m sections from fresh frozen lung tissue were fixed, stained and laser capture microdissected, as previously described 30. Total RNA was isolated and DNase I treated using the Arcturus PicoPure RNA Isolation kit (Arcturus Engineering, Mountain View, CA). cDNA was produced utilising iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). Real time quantitative PCR (Q-PCR) was performed as previously described 8. For copy number analysis 5 μ m sections were briefly de-paraffinised and laser capture microdissected using a Zeiss P.A.L.M. LCM microscope. Genomic DNA was isolated using the QIAamp[®] DNA Micro Kit #56304 and analysed by Taqman or PCR. Copy number Taqman analysis was carried out using the following probes from Applied Biosystems: β -Actin: Mm00607939_s1; Kras: Mm03053281_s1. PCR was performed using the following Kras-specific primers: *Kras*Hind3_F GCCATTAGCTGCTACAAAACAGTA and *Kras*Hind3_R CCTCTATCGTAGGGTCGTACTCAT. Due to the presence of a unique HindIII restriction site in the *Kras*^{G12D} allele, the mutant and *wt* alleles can be distinguished based on their HindIII restriction-digestion profile (WT = 400 bp and *Kras*^{G12D} = 300 +100 bp).

Micro-computed X-ray tomography

Computed tomography (CT) was performed using a micro CT system (FLEXTM X-OTM, Gamma Medica-Ideas, Northridge, CA) with an x-ray source with 75 kVp and 0.315 mA. CT data were acquired as 512 projections over 120 seconds of continuous x-ray exposure. Pre-therapy CT data were acquired as the baseline time point and post-therapy CT performed after 7 days of sustained Tamoxifen administration. Only clearly discrete tumours were picked for volume measurements. Volumes of interest were drawn on axial slices, and the total tumour volumes were calculated planimetrically.

Immunoblot analysis

Whole-cell lysates from dissected tumour halves were prepared and immunoblotted with anti-Spry 2 (Abcam ab50317, Cambridge, MA), Dusp6 (Santa Cruz sc-28902) or β -actin (Sigma A5441, St. Louis, MO) antibodies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We are indebted to T. Jacks for the *KR* mice, C. Sherr and M. Roussel for the p19^{ARF} antibody, M. Dail and A-T. Maia for advice on Kras copy number analysis and V. Weinberg for guidance on statistical analysis. We also thank D. Tuveson and all the members of the Evan laboratory for their sage comments. This work was supported by grants NCI CA98018, NCI CA100193, AICR 09-0649, the Ellison Medical Foundation and from the Samuel R. Waxman Cancer Research Foundation (all to GIE). M.R.J. is the Enrique Cepero, PhD Fellow of the Damon Runyon Cancer Research Foundation.

REFERENCES

1. Jemal A, et al. Cancer statistics, 2006. *CA Cancer J Clin.* 2006; 56:106–130. [PubMed: 16514137]
2. Meuwissen R, Berns A. Mouse models for human lung cancer. *Genes Dev.* 2005; 19:643–664. [PubMed: 15769940]
3. Serrano M, Lin A, McCurrach M, Beach D, Lowe S. Oncogenic *ras* provokes premature cell senescence associated with accumulation of p53 and p16^{INK4a}. *Cell.* 1997; 88:593–602. [PubMed: 9054499]
4. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. *Curr Opin Oncol.* 2008; 20:90–96. [PubMed: 18043262]
5. Jackson EL, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic *K-ras*. *Genes Dev.* 2001; 15:3243–3248. [PubMed: 11751630]
6. Kamijo T, et al. Tumor suppression at the mouse *INK4a* locus mediated by the alternative reading frame product p19^{ARF}. *Cell.* 1997; 91:649–659. [PubMed: 9393858]
7. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. *Cell.* 2006; 127:1323–1334. [PubMed: 17182091]
8. Ventura A, et al. Restoration of p53 function leads to tumour regression in vivo. *Nature.* 2007; 445:661–665. [PubMed: 17251932]
9. Xue W, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature.* 2007; 445:656–660. [PubMed: 17251933]
10. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. *Nature.* 2006; 443:214–217. [PubMed: 16957739]
11. Murphy DJ, et al. Distinct Thresholds Govern Myc's Biological Output In Vivo. *Cancer Cell.* 2008; 14:447–457. [PubMed: 19061836]
12. Sarkisian CJ, et al. Dose-dependent oncogene-induced senescence *in vivo* and its evasion during mammary tumorigenesis. *Nat Cell Biol.* 2007; 9:493–505. [PubMed: 17450133]
13. Sweet-Cordero A, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet.* 2005; 37:48–55. [PubMed: 15608639]
14. Christophorou MA, et al. Temporal dissection of p53 function in vitro and in vivo. *Nat Genet.* 2005; 37:718–726. [PubMed: 15924142]
15. Jackson EL, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. *Cancer Res.* 2005; 65:10280–10288. [PubMed: 16288016]
16. Dulic V, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. *Cell.* 1994; 76:1013–1023. [PubMed: 8137420]

17. El Deiry WS, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. *Cancer Res.* 1994; 54:1169–1174. [PubMed: 8118801]
18. Feldser D, et al. Stage-specific sensitivity to p53 restoration in lung cancer. *Nature.* 2010 In Press.
19. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. *Nature.* 1998; 395:125–126. [PubMed: 9744268]
20. Nikitin AY, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. *Cancer Res.* 2004; 64:2307–2316. [PubMed: 15059877]
21. Guerra C, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. *Cancer Cell.* 2003; 4:111–120. [PubMed: 12957286]
22. Tuveson DA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell.* 2004; 5:375–387. [PubMed: 15093544]
23. Vicent S, et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. *Br J Cancer.* 2004; 90:1047–1052. [PubMed: 14997206]
24. Shaw AT, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. *Genes Dev.* 2007; 21:694–707. [PubMed: 17369402]
25. Wagner P, et al. *In situ* evidence of KRAS amplification and association with increased p21 levels in Non-Small Cell Lung Carcinoma. *American Journal of Clinical Pathology.* 2009; 132:500–505. [PubMed: 19762526]
26. Zhang Z, et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. *Carcinogenesis.* 2010; 31:577–586. [PubMed: 20097731]
27. Zhang Z. Wildtype Kras2 can inhibit lung carcinogenesis in mice. *Nat Genet.* 2001; 29:25–33. [PubMed: 11528387]
28. Junttila MR, Evan GI. p53, a Jack of all trades but master of none. *Nat Rev Cancer.* 2009; 9:821–829. [PubMed: 19776747]
29. Bertwistle D, Zindy F, Sherr CJ, Roussel MF. Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein. *Hybrid Hybridomics.* 2004; 23:293–300. [PubMed: 15672607]
30. Lawlor ER, et al. Reversible Kinetic Analysis of Myc Targets *In vivo* Provides Novel Insights into Myc-Mediated Tumorigenesis. *Cancer Res.* 2006; 66:4591–4601. [PubMed: 16651409]




Figure 1. Heterogeneous therapeutic impact of p53 restoration in *Kras*^{G12D} driven lung tumours
a. Schematic representation of the experimental treatment regime. *Kras*^{G12D} was activated in the lung epithelium of 8 week old *KR;p53*^{KI/KI} mice by adenoviral-Cre nasal inhalation and the resulting tumours treated with Tam or vehicle (Ctrl) 15 weeks after adenoviral infection.
b. Haematoxylin and Eosin staining of lung sections from *KR;p53*^{KI/KI} mice showing tumour load after 7 daily control (Ctrl) or Tam treatments.

- c.** Quantification of Ki67 positive cells per lung tumour from 7 day Tam/Ctrl-treated *KR;p53^{KI/KI}* mice. Error bars indicate standard error of mean (Ctrl: s.e.m=1.20 n=55; Tam: s.e.m=1.31 n=37). * P=0.0003, Student's t-test.
- d.** Percent of apoptotic (TUNEL-positive) tumours (scored as a minimum of 1 positive cell per tumour section) in 7 day Ctrl and Tam treated *KR;p53^{KI/KI}* lungs (n=37 Ctrl; n=22 Tam treated tumours). * P=0.0064, Pearson Chi square.
- e.** *KR;p53^{KI/KI}* lung tumours from *KR;p53^{KI/KI}* treated for 6 hrs with Tam, showing either no discernible TUNEL staining (Neg) or significant levels of TUNEL staining (Pos). Scale bar=100 μ m.




Figure 2. Heterogeneous p53 activation and p19^{ARF} up-regulation in *KR;p53^{KI/KI}* tumours

a. MicroCT-derived plots depicting changes in tumour volume during a 7-day treatment. 10 independent tumours are shown before (day 0) and after (day 7) daily Tam (red lines, filled symbols) or sham (black lines, open symbols) treatments.

b. Taqman analysis of *CDKN1A* expression in individual laser-captured lung tumours from *KR;p53^{KI/KI}* mice treated for 7 days with vehicle (black circles) or Tam (red squares).

Tumours were harvested 24 hrs after the final Ctrl/Tam treatment. Where indicated (IR +,

left panel) mice were exposed to a single dose of γ -radiation 2 hrs after the last Tam/Ctrl treatment. Each circle/square represents a single tumour.

c. IHC data comparing levels of p19^{ARF} expression in low and high-grade tumours as well as in transitional lesions exhibiting both low and high-grade features. Scale bars=50 μ m.

d. Co-immunostaining for p19^{ARF} and p21^{cip1} in *KR;p53^{KI/KI}* lung tumours from mice treated for 6 hrs with Tam. Representative fields shown, one at low (upper panel) and one at high magnification (lower panel). Scale bar=50 μ m.




Figure 3. p53 restoration targets high-grade, but not low-grade, lung tumour cells

a. Co-immunostaining for p19^{ARF} and the proliferation marker Ki67 in lung tumours from *KR;p53^{KI/KI}* mice treated for 24 hrs with vehicle (Ctrl, upper row) or Tam (four lower rows). Row 2 and 3 illustrate the profound anti-proliferative impact (low Ki67) of p53 restoration in tumours with high p19^{ARF} levels. By contrast, the lower two rows show lack of growth inhibition following p53 restoration in tumours lacking detectable p19^{ARF}. Scale bar = 50 μ m.

b. Quantification of low versus high-grade tumour frequencies in lungs of *KR;p53^{KI/KI}* mice treated for 7 days with either vehicle (Ctrl) or Tam (n=143 Ctrl; n=163 Tam). P=0.0001, Pearson Chi square.

c. Representative images show IHC for BrdU in high-grade tumours from 7-day treated Ctrl (Ctrl, upper panel) or Tam mice (lower panel). BrdU was administered 2 hrs before harvesting. Arrows highlight high-grade cells in each tumour (filled, BrdU positive and open, BrdU negative). Scale bars=50 μ m.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. High-grade lung tumours exhibit increased Kras signalling
a. IHC for p19^{ARF} and p-ERK in consecutive sections of three independent low-to-high-grade transition tumours from *KR;p53^{KI/KI}* mice. Scale bar = 200 µm.
b. *Kras* allele analysis was performed on genomic DNA from *KR;p53^{KI/KI}* lung tumours following laser capture microdissection. p-ERK IHC was used to define areas of low, mixed or high p-ERK (upper panel, Scale bar=50µm) and consecutive slides used for LCM of defined regions (see dotted areas). DNA was isolated from LCM material and the *Kras* genomic region amplified by PCR and digested with HindIII (lower panel). For each

tumour, the undigested (–) and digested (+) PCR fragments were run alongside and the wt (*Kras*, higher band) and mutant alleles (G12D, lower band) are indicated. Control lung tissue from heterozygous (*Kras*^{G12D/+}; Ctrl) and wild-type (WT) mice was also analyzed.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript